Tag Archives: Medicaid

The Sovaldi Case: Is American Biotech History About to Repeat Itself?

Recent Congressional investigations over the pricing scheme of Gilead’s much-heralded hepatitis C drug Sovaldi – and a decline in stocks across the biotech sector – rings a familiar bell, writes Tom Norton. Twenty years ago in May, US Senator Joe Lieberman carefully questioned biotech CEO Harry Penner of then Neurogen Corporation about why his company’s […]
Posted in Biotech, healthcare, leadership, Market Access, pricing, R&D, Sales, Strategy | Also tagged , , , , , , , , | 1 Comment

Budget Options Will Reshape Healthcare

While the struggle continues in 2014 to provide effective and affordable coverage, administration and Congressional leaders will weigh a host of spending options important to coverage and delivery. Federal outlays for healthcare and health-related federal tax benefits exceed $1 trillion a year, according to the Congressional Budget Office (CBO). These and related spending on discretionary […]
Posted in Guest Blog, healthcare, Regulatory | Also tagged , , | Leave a comment

Obamacare and U.S. Pharma: Two Months In

U.S. Pharma in the Eye of the Obamacare Storm So, we’ve experienced two months of Obamacare.  How is the U.S. pharmaceutical industry doing with this new program?  I spent two weeks getting the opinions of several Rx representatives on their experience with Obamacare, as well as their thoughts on how it is impacting their marketing, […]
Posted in Guest Blog, healthcare, Op-Ed, Regulatory | Also tagged , , | 1 Comment

Feds Take a Pass on Co-Pay Offsets Under Obamacare

Feds Take a Pass on Co-Pay Offsets Under Obamacare The implosion of the Affordable Care Act’s vaunted healthcare.gov benefit enrollment process has obscured a far more critical issue for big Pharma:  how much leeway do companies have in promoting durable brand affiliations among the potentially millions of new patients with subsidized access to new  medicines? […]
Posted in healthcare, Regulatory | Also tagged , , , , | Leave a comment

Co-Pay Offset Programs and the New Health Insurance Marketplace: Will the Feds Say No?

By Mark McAndrew. As the health insurance marketplaces begin enrollment this week and go live on January 1, 2014, several issues continue to be a source of significant confusion to manufacturers, payers and the millions of consumers purchasing health insurance for the first time through an exchange.  Many of these issues, such as the cost […]
Posted in Guest Blog, healthcare, Op-Ed, Regulatory | Also tagged , , , , , , , , | Leave a comment
  • Categories

  • Meta